Francois Cedric's most recent trade in Apellis Pharmaceuticals Inc was a trade of 287,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 287,500 | 287,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 2,824 | 415,695 (0%) | 0% | 29.5 | 83,375 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 13,551 | 418,519 (0%) | 0% | 30.4 | 412,296 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 130,662 | 432,070 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 6,007 | 301,408 (0%) | 0% | 30.0 | 179,959 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 6,247 | 307,415 (0%) | 0% | 28.7 | 179,302 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 01 Nov 2024 | 182,146 | 472,065 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 01 Mar 2024 | 200,000 | 563,662 (0%) | 0% | 4.3 | 862,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 200,000 | 175,538 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.92 per share. | 01 Mar 2024 | 116,512 | 314,075 (0%) | 0% | 64.9 | 7,563,528 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.26 per share. | 01 Mar 2024 | 62,503 | 430,587 (0%) | 0% | 64.3 | 4,016,274 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 01 Mar 2024 | 50,000 | 363,662 (0%) | 0% | 3.8 | 188,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 8,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 62.96 per share. | 01 Mar 2024 | 41,704 | 493,090 (0%) | 0% | 63.0 | 2,625,813 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 62.21 per share. | 01 Mar 2024 | 28,868 | 534,794 (0%) | 0% | 62.2 | 1,795,965 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.68 per share. | 01 Mar 2024 | 413 | 313,662 (0%) | 0% | 65.7 | 27,126 | Common Stock |
| Apellis Pharmaceuticals Inc | Francois Cedric | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.77 per share. | 12 Feb 2024 | 3,962 | 313,662 (0%) | 0% | 67.8 | 268,492 | Common Stock |
| Apellis Pharmaceuticals Inc | Francois Cedric | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 29 Jan 2024 | 2,843 | 317,624 (0%) | 0% | 64.1 | 182,345 | Common Stock |
| Apellis Pharmaceuticals Inc | Francois Cedric | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 13,431 | 320,467 (0%) | 0% | 65.0 | 872,961 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 01 Sep 2023 | 300,000 | 574,655 (0%) | 0% | 2.7 | 801,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2023 | 300,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.70 per share. | 01 Sep 2023 | 139,716 | 434,939 (0%) | 0% | 41.7 | 5,826,506 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.44 per share. | 01 Sep 2023 | 10,284 | 424,655 (0%) | 0% | 42.4 | 436,453 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 May 2023 | 20,000 | 654,211 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 May 2023 | 20,000 | 274,655 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 30,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 16 May 2023 | 30,000 | 304,655 (0%) | 0% | 2.7 | 80,100 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 20,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 16 May 2023 | 20,000 | 294,655 (0%) | 0% | 2.7 | 53,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.01 per share. | 16 May 2023 | 14,611 | 287,310 (0%) | 0% | 85.0 | 1,242,065 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.02 per share. | 16 May 2023 | 7,528 | 276,775 (0%) | 0% | 87.0 | 655,059 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.90 per share. | 16 May 2023 | 3,007 | 284,303 (0%) | 0% | 85.9 | 258,305 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.67 per share. | 16 May 2023 | 2,120 | 274,655 (0%) | 0% | 87.7 | 185,869 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.84 per share. | 16 May 2023 | 1,800 | 301,921 (0%) | 0% | 83.8 | 150,921 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.17 per share. | 16 May 2023 | 934 | 303,721 (0%) | 0% | 83.2 | 77,682 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2023 | 30,000 | 370,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.02 per share. | 18 Apr 2023 | 30,000 | 637,601 (0%) | 0% | 82.0 | 2,460,720 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 18 Apr 2023 | 30,000 | 667,601 (0%) | 0% | 2.7 | 80,100 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 18 Apr 2023 | 20,000 | 657,601 (0%) | 0% | 2.7 | 53,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2023 | 20,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 380,000 | 607,221 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 380,000 | 664,591 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 227,221 | 227,221 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 227,221 | 1,044,591 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 26,990 | 634,211 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2023 | 26,990 | 637,601 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 100,000 | 58,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 21 Mar 2023 | 100,000 | 1,264,591 (1%) | 0% | 3.8 | 376,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 21 Mar 2023 | 30,000 | 1,174,591 (1%) | 0% | 2.7 | 80,100 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 62.74 per share. | 21 Mar 2023 | 30,000 | 1,144,591 (1%) | 0% | 62.7 | 1,882,332 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 30,000 | 420,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 21 Mar 2023 | 20,000 | 1,164,591 (1%) | 0% | 2.7 | 53,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 20,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 7,221 | 273,779 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 21 Mar 2023 | 7,221 | 1,271,812 (1%) | 0% | 13.9 | 100,011 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 100,000 | 158,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 27 Feb 2023 | 100,000 | 1,144,591 (1%) | 0% | 3.8 | 376,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 19,728 | 19,728 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 13,908 | 1,046,193 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 1,602 | 1,044,591 (1%) | 0% | 58.5 | 93,717 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. | 10 Feb 2023 | 3,958 | 1,032,285 (1%) | 0% | 51.2 | 202,689 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 27 Jan 2023 | 2,879 | 1,036,243 (1%) | 0% | 52.8 | 151,925 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 9,453 | 1,039,122 (1%) | 0% | 52.1 | 492,029 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 131,093 | 131,093 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 83,447 | 1,048,575 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 25 Apr 2022 | 75,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 25 Apr 2022 | 28,200 | 971,640 (1%) | 0% | 2.7 | 75,294 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 28,200 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.07 per share. | 25 Apr 2022 | 24,449 | 965,128 (1%) | 0% | 52.1 | 1,273,052 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 25 Apr 2022 | 15,000 | 986,640 (1%) | 0% | 3.8 | 56,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 15,000 | 258,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 25 Apr 2022 | 12,500 | 943,440 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.95 per share. | 25 Apr 2022 | 6,688 | 993,328 (1%) | 0% | 15.0 | 99,986 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 6,688 | 273,312 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.97 per share. | 25 Apr 2022 | 3,751 | 989,577 (1%) | 0% | 52.0 | 194,931 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 2,523 | 955,940 (1%) | 0% | 47.1 | 118,884 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 2,024 | 1,338,463 (1%) | 0% | 38.6 | 78,106 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 150,672 | 150,672 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 106,244 | 1,340,487 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 14,410 | 375,538 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 21 Jul 2021 | 14,410 | 1,234,243 (1%) | 0% | 4.3 | 62,107 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. | 10 Feb 2021 | 2,523 | 1,219,833 (1%) | 0% | 47.7 | 120,398 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 25,000 | 1,209,856 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 12,500 | 1,222,356 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 27 Jan 2021 | 39,785 | 1,152,864 (1%) | 0% | 3.8 | 149,592 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 39,785 | 273,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 31,992 | 389,948 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 27 Jan 2021 | 31,992 | 1,184,856 (1%) | 0% | 4.3 | 137,886 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.16 per share. | 15 Dec 2020 | 5,000 | 1,113,079 (1%) | 0% | 52.2 | 260,800 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 01 Dec 2020 | 40,000 | 1,118,079 (1%) | 0% | 3.8 | 150,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 40,000 | 313,625 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.38 per share. | 16 Nov 2020 | 5,000 | 1,078,079 (1%) | 0% | 39.4 | 196,900 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.46 per share. | 15 Oct 2020 | 5,000 | 1,083,079 (1%) | 0% | 34.5 | 172,300 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.96 per share. | 15 Sep 2020 | 5,000 | 1,088,079 (1%) | 0% | 31.0 | 154,800 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 20 Aug 2020 | 3,457 | 1,093,079 (1%) | 0% | 30 | 103,710 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Aug 2020 | 1,543 | 1,096,536 (1%) | 0% | 30 | 46,290 | Common Stock |
| Apellis Pharmaceuticals Inc | Cedric Francois | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.12 per share. | 15 Jul 2020 | 5,000 | 1,098,079 (1%) | 0% | 32.1 | 160,600 | Common Stock |